Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.

Chen, M ; Jin, Y ; et al.

In: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, Jg. 132 (2016), Heft 1, S. 34-8

Online academicJournal

Wie komme ich dran?

Zugriff:

Full Text Finder (Volltext)

Objective: To investigate the oncologic and reproductive outcomes after progestin treatment of complex endometrial hyperplasia (CEH) and grade 1 endometrial carcinoma (EC).

Methods: In a retrospective study, data were obtained for patients aged 20-42years with CEH or grade 1 EC at presumed stage IA (without myometrial invasion) who wished to preserve fertility and were treated at the Peking Union Medical College Hospital, China, between January 1, 2000, and December 31, 2011. Patients had received oral medroxyprogesterone acetate (250-500mg/day) or megestrol acetate (160-480mg/day) for at least 6months. Response to progestin treatment was assessed histologically.

Results: Among 53 included patients, 39 (74%) achieved complete response after a median period of 6 (3-24) months. Complete response was less frequent among obese than nonobese patients (4/12 [33%] vs 35/41 [85%]; P=0.001). Disease recurrence was recorded in 10 (26%) patients with complete response; the 5-year recurrence-free survival rate was 71%. Among the 33 patients who retained a desire to conceive, 17 (52%) became pregnant.

Conclusion: Fertility-sparing management with oral progestin is effective. Obesity is associated with a lower probability of long-term success.

Titel:	Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Autor/in / Beteiligte Person:	Chen, M ; Jin, Y ; Li, Y ; Bi, Y ; Shan, Y ; Pan, L
Link:	Full Text Finder (Volltext)
Zeitschrift:	International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, Jg. 132 (2016), Heft 1, S. 34-8
Veröffentlichung:	2017- : Malden, MA : Wiley ; <i>Original Publication</i>: [New York, NY] Hoeber Medical Division, Harper & Row, [c1969-, 2016
Medientyp:	academicJournal
ISSN:	1879-3479 (electronic)
DOI:	10.1016/j.ijgo.2015.06.046
Schlagwort:	Adult China Disease-Free Survival Female Fertility drug effects Humans Medroxyprogesterone Acetate administration & dosage Megestrol Acetate administration & dosage Neoplasm Recurrence, Local Obesity complications Pregnancy Recurrence Retrospective Studies Treatment Outcome Young Adult Antineoplastic Agents, Hormonal administration & dosage Endometrial Hyperplasia drug therapy Endometrial Neoplasms drug therapy Fertility Preservation methods Progestins administration & dosage
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Evaluation Study; Journal Article Language: English [Int J Gynaecol Obstet] 2016 Jan; Vol. 132 (1), pp. 34-8. <i>Date of Electronic Publication: </i>2015 Oct 01. MeSH Terms: Antineoplastic Agents, Hormonal / administration & dosage ; Endometrial Hyperplasia / drug therapy ; Endometrial Neoplasms / drug therapy ; Fertility Preservation / methods ; Progestins / *administration & dosage ; Adult ; China ; Disease-Free Survival ; Female ; Fertility / drug effects ; Humans ; Medroxyprogesterone Acetate / administration & dosage ; Megestrol Acetate / administration & dosage ; Neoplasm Recurrence, Local ; Obesity / complications ; Pregnancy ; Recurrence ; Retrospective Studies ; Treatment Outcome ; Young Adult Contributed Indexing: Keywords: Complex endometrial hyperplasia; Conservative treatment; Endometrial carcinoma; Fertility-sparing treatment; Progestin therapy Substance Nomenclature: 0 (Antineoplastic Agents, Hormonal) ; 0 (Progestins) ; C2QI4IOI2G (Medroxyprogesterone Acetate) ; TJ2M0FR8ES (Megestrol Acetate) Entry Date(s): Date Created: 20151024 Date Completed: 20161014 Latest Revision: 20191210 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.